NASDAQ:IDXX - IDEXX Laboratories Stock Price, Forecast & News

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

IDEXX Laboratories declared that its Board of Directors has initiated a stock repurchase plan on Wednesday, February 12th 2020, which permits the company to buyback 5,000,000 outstanding shares, according to EventVestor. This buyback authorization permits the company to repurchase shares of its stock through open market purchases. Stock buyback plans are usually a sign that the company's leadership believes its stock is undervalued.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced its quarterly earnings results on Friday, January, 31st. The company reported $1.04 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.91 by $0.13. The business earned $605.50 million during the quarter, compared to analysts' expectations of $600.60 million. IDEXX Laboratories had a net margin of 17.77% and a return on equity of 283.27%. The company's revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the previous year, the company earned $0.98 earnings per share. View IDEXX Laboratories' Earnings History.

IDEXX Laboratories is scheduled to release their next quarterly earnings announcement on Wednesday, May 6th 2020. View Earnings Estimates for IDEXX Laboratories.

IDEXX Laboratories issued an update on its FY20 earnings guidance on Friday, January, 31st. The company provided earnings per share (EPS) guidance of $5.42-5.58 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.41. The company issued revenue guidance of $2.62-2.66 billion, compared to the consensus revenue estimate of $2.63 billion.

6 analysts have issued 12 month price objectives for IDEXX Laboratories' shares. Their forecasts range from $277.00 to $310.00. On average, they expect IDEXX Laboratories' stock price to reach $293.33 in the next twelve months. This suggests a possible upside of 14.3% from the stock's current price. View Analyst Price Targets for IDEXX Laboratories.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IDEXX Laboratories.

News stories about IDXX stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. IDEXX Laboratories earned a news sentiment score of 1.8 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for IDEXX Laboratories.

IDEXX Laboratories saw a decline in short interest in the month of January. As of January 31st, there was short interest totalling 1,210,000 shares, a decline of 6.9% from the January 15th total of 1,300,000 shares. Based on an average daily volume of 507,000 shares, the short-interest ratio is presently 2.4 days. Approximately 1.4% of the company's stock are short sold. View IDEXX Laboratories' Current Options Chain.

Some companies that are related to IDEXX Laboratories include Medtronic (MDT), Abbott Laboratories (ABT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), Teleflex (TFX), Steris (STE), Hologic (HOLX), Insulet (PODD) and Varian Medical Systems (VAR).

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Paypal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Adobe (ADBE), Mastercard (MA), Intuitive Surgical (ISRG), Home Depot (HD), Micron Technology (MU) and Walt Disney (DIS).

IDEXX Laboratories' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include State Street Corp (4.40%), Bamco Inc. NY (4.39%), Geode Capital Management LLC (1.82%), Blair William & Co. IL (1.80%), Principal Financial Group Inc. (1.39%) and Capital World Investors (1.28%). Company insiders that own IDEXX Laboratories stock include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jay Mazelsky, Jonathan W Ayers, Lawrence D Kingsley, M Anne Szostak, Michael Lane, Rebecca M Henderson, Sophie V Vandebroek and William T End. View Institutional Ownership Trends for IDEXX Laboratories.

IDXX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Marshall Wace North America L.P., Skandinaviska Enskilda Banken AB publ , Bamco Inc. NY, Massachusetts Financial Services Co. MA, MERIAN GLOBAL INVESTORS UK Ltd, MERIAN GLOBAL INVESTORS UK Ltd and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Giovani Twigge, Jacqueline Studer, Jay Mazelsky, Jonathan W Ayers, M Anne Szostak, Michael Lane, Rebecca M Henderson and Sophie V Vandebroek. View Insider Buying and Selling for IDEXX Laboratories.

IDXX stock was purchased by a variety of institutional investors in the last quarter, including KBC Group NV, Robeco Institutional Asset Management B.V., Beacon Investment Advisory Services Inc., State Street Corp, Credit Suisse AG, Bank of Montreal Can, Great Diamond Partners LLC and Geode Capital Management LLC. Company insiders that have bought IDEXX Laboratories stock in the last two years include Bruce L Claflin and Lawrence D Kingsley. View Insider Buying and Selling for IDEXX Laboratories.

Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IDXX stock can currently be purchased for approximately $256.71.

IDEXX Laboratories has a market capitalization of $21.91 billion and generates $2.41 billion in revenue each year. The company earns $427.72 million in net income (profit) each year or $4.89 on an earnings per share basis. IDEXX Laboratories employs 9,200 workers across the globe.View Additional Information About IDEXX Laboratories.

The official website for IDEXX Laboratories is http://www.idexx.com/.

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected]